A blockbuster drug made by Amgen is no more effective than a cocktail of cheaper generic therapies in treating a severe joint disease affecting an estimated 1.3 million Americans, according to a new study funded by the Department of Veterans Affairs.
Amgen drug faces challenge
Letter
to the
Editor
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.
Sponsored Content